News

In the month of March, not only did trials progress, but approvals for new and expanded uses of treatments were issued.

The authors examined vascular and neural structures in the eye, assessing the foveal avascular zone and choroidal thickness

The approval makes ILM-Blue the first DORC posterior dye product available in China, according to a press release from Zeiss

One intravitreal injection of the dexamethasone implant in patients with refractory DME induced significant anatomic and functional improvements, but these improvements only lasted for short periods of up to 4 months.

Administered via intravitreal injection, Synthopsin-MCO-010 possesses a promoter to specifically target ON-bipolar cells.

The funding will help fund phase 1 and phase 2 proof-of-concept studies for lead candidates CTX203 and CTX114.

The partnership will use ocular imaging to build an AI foundation model and identify new genetic targets for degenerative diseases

ZEISS VISULAS Combi is an advanced therapeutic laser workstation offering photodisruption, photocoagulation, and slit lamp technology in a single, comprehensive solution.

The trial evaluated sozinibercept (2 mg) every 4 or 8 weeks in combination with aflibercept (2 mg), as per label, every 8 weeks after a loading phase for the treatment of wet AMD.

UBX1325 is a novel BCL-xL inhibitor designed to eliminate senescent cells in diabetic retinal blood vessels, while leaving healthy ones intact.

A retrospective study showed that the gender of the ophthalmologist influenced the amount of communication with the patient, and that the pandemic had an impact.

After review by the Data and Safety Monitoring Board, the dosing of OCU200 in patients with diabetic macular edema (DME) will continue.

The recent agreement with Cipla adds to the list of partnerships Formosa has formed for APP13007.

Investigators advised clinicians of the potential for dystrophies that mimic age-related macular degeneration and other atrophic macular pathologies to be incorrectly diagnosed, which can impact treatment.

The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading dose of a minimum of three monthly intravitreal aflibercept injections that was followed by a TAE.

This treatment is already approved for both diabetic macular edema (DME) and NIU-PS outside the US, including in 17 European countries.

Among the promising areas of retinal disease research are innovative approaches targeting pan-vascular endothelial growth factor inhibition.

The findings of this model support KIO-104 as a promising therapeutic candidate for both the prevention and treatment of PVR.

Maria Vittoria Cicinelli, MD, Denise Loya-Garcia, MD, PhD, and Vishal Raval, MD, were announced as the recipients and will receive a $3,000 honorarium.

The closing of the merger is expected to occur as soon as practicable, subject to the satisfaction or waiver of the remaining customary closing conditions.

Systemic evaluation key to the cause of the detachments

The award honors Ludwig von Sallmann, MD, a “distinguished international ophthalmologist and ophthalmic investigator whose contributions greatly increased the basic and clinical understanding of vision and ophthalmology.”

SpliceBio continues to actively enroll patients in the ASTRA study and accompanying POLARIS trial

Yu reviewed the benefits and limitations of various electrophysiologic technologies in a diverse group of inflammatory conditions affecting the retina and optic nerve.

The ReNEW study for dry AMD is evaluating the efficacy, safety, and pharmacokinetics of daily subcutaneous injections of elamipretide, wa first-in-class mitochondria-targeted investigational therapeutic.

Tarcocimab is an investigational anti-VEGF therapy built on Kodiak's proprietary antibody biopolymer conjugate (ABC) platform.

Hashad is a retinal specialist with over 25 years of leadership experience in global research and development.

Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported

4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection.